Systemic, vascular diseases and ageing

Summary

The Systemic, Vascular Diseases and Ageing group studies the impact and treatment of systemic diseases (i.e. diseases affecting more than one organ) from the clinical and epidemiological perspective to the lab setting. Its area of experience includes the fields of systemic autoimmune diseases, venous thromboembolic disease, ageing (mainly chronic heart failure) and hemorrhagic hereditary telangiectasia and other vascular rare diseases. Regarding rare diseases, this group also studies these diseases from the basic research, with cellular and animal models. In fact, we practice a real translational research, transfering the insights from a laboratory environment into a clinical one, avoiding any gap in the transition between both settings.

1452

Publications

Strategic lines

Autoimmune, autoinflammatory and systemic diseases
Chronicity and aging
Venous thromboembolic disease
Hereditary hemorrhagic telangiectasia and other vascular rare diseases
Minority vascular and storage diseases
Adult immunopathies
Allergology
Cardiovascular risk factors and atherosclerosis
Complex dyslipidemias
Angiogenesis and blood vessel remodeling
Leukocyte extravasation and inflammation

Selected Publications

Riedl,MA;Farkas,H;Aygören Pürsün,E;Psarros,F;Soteres,DF;Staevska,M;Cancian,M et al, Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks, N Engl J Med, 2024;391(1):32-43, doi:10.1056/NEJMoa2314192
Villanueva,B;Sánchez Corral,MÁ;Alba,E;Ordi,Q;Ruiz,Y;Torres Iglesias,R;Portillo,A et al, Long-term follow-up of hereditary hemorrhagic telangiectasia patients without significant pulmonary right-to-left shunt at screening., Eur. J. Intern. Med., 2024;132106-112, doi:10.1016/j.ejim.2024.12.006
Sánchez Marteles,M;Garcés Horna,V;Morales Rull,JL;Casado,J;Carrera Izquierdo,M;Conde Martel,A;Dávila Ramos,MF et al, Combining Loop and Thiazide DiureticsAcross the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial., JACC-Heart Fail., 2024;12(10):1719-1730, doi:10.1016/j.jchf.2024.05.006
van Splunder,H;Villacampa,P;Martínez Romero,A;Graupera,M, Pericytes in the disease spotlight., Trends Cell Biol, 2024;34(1):58-71, doi:10.1016/j.tcb.2023.06.001
Khoury,N;Martínez,MA;Nishi,SK;Martinez Gonzalez,MA;Corella,D;Castañer,O;Martinez,JA et al, Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population, Environ. Int., 2024;186doi:10.1016/j.envint.2024.108565

Selected Projects

2022-000160-22. ESTUDIO DEMOSTRATIVO PRELIMINAR, ALEATORIZADO, CONTROLADO CON PLACEBO, CON DOBLE ENMASCARAMIENTO, MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DOS DOSIS DE VAD044 EN PACIENTES CON TELANGIECTASIA HEMORRÁGICA HEREDITARIA (THH). Vaderis Therapeutics AG. Budget: 255.000€. 2022-2024. PI: ANTONI RIERA MESTRE.
2023-509190-23. Estudio de fase 3, aleatorizado, con enmascaramiento doble, comparativo con un placebo, para investigar el efecto de Leposidisirán sobre la reducción de los acontecimientos cardiovasculares adversos graves en adultos que presenten elevación de la lipoproteína(a) y enfermedad cardiovascular ateroesclerótica confirmada o riesgo de sufrir un primer acontecimiento cardiovascular – ACCLAIM-LP (A). Eli Lilly and Company. Budget: 461.838,37€. 2024- . PI: JAVIER PINTO SALA.
PI23/00164. Nuevo conocimiento en el desarrollo de malformaciones vasculares hepáticas en los pacientes con Telangiectasia Hemorrágica Hereditaria. Instituto de Salud Carlos III (ISCIII). Budget: 167.500€. 2024-2026. PI: RIERA MESTRE, ANTONI.
PI23/00651. Papel de los autoanticuerpos que neutralizan interferones de tipo I en el lupus eritematoso sistémico. Instituto de Salud Carlos III (ISCIII). Budget: 202.500€. 2024-2026. PI: SOLANICH MORENO, XAVIER.
202115-31. Role of immune system inborn errors as determinants of the COVID-19 severity in hospitalized patients. Fundació La Marató de TV3. Budget: 128.123,85€. 2021-2024. PI: SOLANICH MORENO, XAVIER.